Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma
Open Access
- 23 March 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 11 (1), 14
- https://doi.org/10.1186/1476-4598-11-14
Abstract
Background: We had previously demonstrated overexpression of fibroblast growth factor receptor-4 (FGFR4) in hepatocellular carcinoma (HCC). However, additional molecular mechanisms resulting in amplified FGFR4 signaling in HCC remain under-studied. Here, we studied the mechanistic role of its co-receptor klotho-beta (KLB) in driving elevated FGFR4 activity in HCC progression. Results: Quantitative real-time PCR analysis identified frequent elevation of KLB gene expression in HCC tumors relative to matched non-tumor tissue, with a more than two-fold increase correlating with development of multiple tumors in patients. KLB-silencing in Huh7 cells decreased cell proliferation and suppressed FGFR4 downstream signaling. While transient repression of KLB-FGFR4 signaling decreased protein expression of alpha-fetoprotein (AFP), a HCC diagnostic marker, prolonged inhibition enriched for resistant HCC cells exhibiting increased liver stemness. Conclusions: Elevated KLB expression in HCC tissues provides further credence to the oncogenic role of increased FGFR4 signaling in HCC progression and represents a novel biomarker to identify additional patients amenable to anti-FGFR4 therapy. The restricted tissue expression profile of KLB, together with the anti-proliferative effect observed with KLB-silencing, also qualifies it as a specific and potent therapeutic target for HCC patients. The enrichment of a liver stem cell-like population in response to extended KLB-FGFR4 repression necessitates further investigation to target the development of drug resistance.Keywords
This publication has 35 references indexed in Scilit:
- Metabolic Regulator βKlotho Interacts with Fibroblast Growth Factor Receptor 4 (FGFR4) to Induce Apoptosis and Inhibit Tumor Cell Proliferation*Online Journal of Public Health Informatics, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 ActivationOnline Journal of Public Health Informatics, 2010
- Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesisMolecular Carcinogenesis, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Molecular targeted therapies in hepatocellular carcinomaJournal of Hepatology, 2008
- Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21Journal of Biological Chemistry, 2007
- Human hepatic stem cells from fetal and postnatal donorsThe Journal of Experimental Medicine, 2007
- βKlotho is required for metabolic activity of fibroblast growth factor 21Proceedings of the National Academy of Sciences of the United States of America, 2007
- Hepatic progenitor cells, stem cells, and AFP expression in models of liver injuryInternational Journal of Experimental Pathology, 2006